Epigenomics, Kindstar Global Co. Ltd. sales and marketing update

Epigenomics granted Kindstar exclusive rights to develop and commercialize the Epi proLung BL Reflex assay for use in lung cancer diagnosis in China. Kindstar will be responsible for regulatory activities in China. Epigenomics will be responsible for manufacturing and supply and will provide Kindstar with material, equipment, training of laboratory staff and regulatory support. Epigenomics said no milestones or royalties will be paid, but Kindstar has committed to purchase a minimum number of tests at an agreed price. Kindstar could not be reached for details. ...